DGX Quest Diagnostics

company

SEC Filings & Insider Trading Activity 2026

Management Discussion & Analysis

• • Revenue $11.0B in FY2025; no explicit YoY dollar comparison provided in the MD&A text
• • Advanced Diagnostics segment — oncology, cardiometabolic, brain health, autoimmune, women's health/genetics — exceeded $1B revenue on double-digit growth
• • Hospital channel: reference testing ~$1.2B; Collaborative Lab Solutions ~$800M in 2025
• • Capital return: quarterly dividend raised ~7.5% to $0.86/share; ~$8.1B returned via buybacks since 2012
• • Key risks: PAMA reimbursement reform pending, Project Nova IT modernization through 2031–2032, and evolving AI/regulatory landscape

Risk Factors

• • PAMA reimbursement reform risk: Congress introduced 2025 Results Act to fix structural flaws; prior 2018-2020 cuts exceeded original 10-year savings projections
• • Debt load $5.7B outstanding as of Dec 31, 2025 with restrictive covenants limiting operational flexibility
• • IT modernization via multi-year Project Nova, partnered with Epic; system failure could disrupt billing and customer service operations
• • AI-enabled point-of-care and home testing competitors threatening volume; hospitals internalizing advanced testing without commercial labs
• • Tariffs and trade policy uncertainty raising supply chain costs for testing equipment and materials across international operations

Business Overview

• • Largest national lab services provider: ~$11.0B net revenue in 2025, serving ~⅓ of U.S. adult population annually and processing 244 million test requisitions
• • Advanced Diagnostics™ five-franchise segment (oncology, cardiometabolic, brain health, autoimmune, women's health) surpassed $1B revenue on double-digit growth
• • Haystack Oncology MRD ctDNA test received FDA Breakthrough Device Designation in 2025 for early-stage colorectal cancer, with clinical trials launched at Mass General Brigham and Rutgers Cancer Institute
• • Project Nova launched Feb 2025: multi-year Epic-powered "Order to Cash" modernization targeting completion 2031–2032; Google Cloud generative AI collaboration also announced in 2025
• • LifeLabs acquisition (2024) added ~6,800 employees and ~23 million Canadian test requisitions in first full year, bringing global headcount to nearly 57,000

What are the latest DGX SEC filings in 2026?

Quest Diagnostics (DGX) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on April 22, 2026, an 8-K current report on July 23, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did DGX file its most recent 10-K annual report?

Quest Diagnostics (DGX) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view DGX 10-Q quarterly reports?

Quest Diagnostics (DGX)'s most recent 10-Q quarterly report was filed on April 22, 2026. SignalX displays every DGX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has DGX filed recently?

Quest Diagnostics (DGX)'s most recent 8-K was filed on July 23, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find DGX insider trading activity (Form 4)?

SignalX aggregates every DGX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does DGX file with the SEC?

Quest Diagnostics (DGX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new DGX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Quest Diagnostics (DGX).

What is DGX's SEC CIK number?

Quest Diagnostics (DGX)'s SEC CIK (Central Index Key) number is 1022079. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1022079 to look up all DGX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find DGX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Quest Diagnostics (DGX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.